Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.

OBJECTIVE To determine in vivo the extent of damage to, and changes in turnover of, articular cartilage type II collagen (CII) and the proteoglycan aggrecan following the onset of inflammatory arthritis in humans, and to examine the hypothesis that there are direct relationships between cartilage biomarkers of damage/turnover and clinical, histologic, and molecular markers of inflammation. METHODS Synovial fluid (SF) and synovial membrane (SM) were obtained by arthroscopy, and a synovitis score was determined, in 32 patients with rheumatoid arthritis (RA) (13 with early untreated disease, 19 with established disease), 18 with psoriatic arthritis (PsA), and 10 with osteoarthritis (OA). Systemic disease activity markers were recorded, and SM CD3+ T cells, CD4+ T cells, CD68+ macrophages, and lining layer hyperplasia were quantified. SF levels of tumor necrosis factor alpha (TNFalpha), interleukin-10 (IL-10), matrix metalloproteinase 1 (MMP-1), MMP-3, Col2-3/4C(Long mono) neoepitope (C2C) (reflecting collagenase cleavage of cartilage CII), C-propeptide of type II procollagen (PIICP) (a biosynthesis marker), keratan sulfate (KS), and the 846 epitope of aggrecan (turnover) were measured by enzyme-linked immunosorbent assay or radioimmunoassay. RESULTS Levels of cartilage degradation products in early RA or early PsA were not elevated above levels in OA, although in early inflammatory arthritis, TNFalpha and MMP-1 levels were similar to those observed in late inflammatory disease and higher than those in OA. PIICP was reduced in early RA. Correlations were observed between the SF C2C neoepitope level and the Health Assessment Questionnaire score, C-reactive protein level, plasma viscosity, synovitis score, and SF TNFalpha and MMP-1 levels. KS epitope content was reduced in direct relation to SM macrophage infiltration in the sublining and lining layers and in the presence of elevated SF MMP-3. Both SF MMP-1 and SF MMP-3 levels correlated with CD4+ T cell infiltration and lining layer hyperplasia in the SM, and MMP-1 levels correlated with lining layer CD68 levels, but TNFalpha and IL-10 levels did not. CONCLUSION Except for CII synthesis, there were no significant changes in extracellular matrix turnover of aggrecan or CII in the early stages of human inflammatory arthritis. However, the direct correlation between the increases in TNFalpha and MMP-1 production and collagen degradation suggests that collagenase cleavage of cartilage collagen is related to the activities of TNFalpha and MMP-1. The reduction in CII synthesis in early RA may contribute to the developing pathology, since a lack of synthesis of this molecule would inhibit maintenance of cartilage matrix.

[1]  A. Poole,et al.  Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. , 1992, The Journal of clinical investigation.

[2]  Y. Yoshihara,et al.  Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. , 1993, Osteoarthritis and cartilage.

[3]  Andreas Radbruch,et al.  The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. , 1999, Rheumatology.

[4]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[5]  Mauro Alini,et al.  9 – Cellular Biology of Cartilage Degradation , 1995 .

[6]  Y. Okada,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis , 2000, Annals of the rheumatic diseases.

[7]  B. Bresnihan,et al.  Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. , 1999, Rheumatology.

[8]  C. Rorabeck,et al.  Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.

[9]  N. Ishiguro,et al.  Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. , 1999, Arthritis and rheumatism.

[10]  D. Taylor,et al.  Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. , 1994, Annals of the rheumatic diseases.

[11]  T. Sawai,et al.  Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. , 1995, Annals of the rheumatic diseases.

[12]  廣畑 和志,et al.  Cartilage in health and disease , 1985 .

[13]  N. Fujimoto,et al.  Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[14]  C. Rorabeck,et al.  Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. , 1995, The Journal of clinical investigation.

[15]  G. R. Dodge,et al.  Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. , 1989, The Journal of clinical investigation.

[16]  A. Poole,et al.  Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. , 2001, Arthritis and rheumatism.

[17]  P. Dieppe,et al.  Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. , 1994, The Journal of clinical investigation.

[18]  H. Roos,et al.  Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. , 1996, The Journal of rheumatology.

[19]  D. Veale,et al.  Classification of clinical subsets in psoriatic arthritis. , 1994, British journal of rheumatology.

[20]  A. Poole,et al.  Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[21]  P. Dieppe,et al.  Evidence for altered synthesis of type II collagen in patients with osteoarthritis. , 1998, The Journal of clinical investigation.

[22]  E. Thonar,et al.  Serum keratan sulfate levels in osteoarthritis patients. , 1988, Arthritis and rheumatism.

[23]  Michael J. Green,et al.  The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. , 1999, Arthritis and rheumatism.

[24]  G. Verbruggen,et al.  Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity , 2000, Annals of the rheumatic diseases.

[25]  A. So,et al.  Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. , 1999, Rheumatology.

[26]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[27]  G. Burmester,et al.  Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. , 1999, The Journal of rheumatology.

[28]  J. Farrés,et al.  Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies , 2000, Annals of the rheumatic diseases.

[29]  Mainardi Cl Biochemical mechanisms of articular destruction. , 1987 .

[30]  Y. Yoshihara,et al.  Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. , 1995, The Journal of rheumatology. Supplement.

[31]  P. Emery,et al.  Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[32]  C. Richards,et al.  Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro. , 1997, Arthritis and rheumatism.

[33]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[34]  B. Hazleman,et al.  The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[35]  E. Thonar,et al.  Quantification of keratan sulfate in blood as a marker of cartilage catabolism. , 1985, The Journal of rheumatology.

[36]  J. Ridgway,et al.  Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology , 1999, Annals of the rheumatic diseases.

[37]  E. Thonar,et al.  Body fluid markers of cartilage changes in osteoarthritis. , 1993, Rheumatic diseases clinics of North America.

[38]  Andreas Radbruch,et al.  Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. , 2000, Arthritis and rheumatism.

[39]  F. Arnett Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[40]  P. Dieppe,et al.  Biological markers in rheumatoid arthritis. , 1994, Seminars in arthritis and rheumatism.

[41]  N. Fujimoto,et al.  Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[42]  A. Poole,et al.  Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. , 1999, Arthritis and rheumatism.

[43]  A. Simon,et al.  Divergent T-cell cytokine patterns in inflammatory arthritis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[45]  A. Poole,et al.  Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. , 1990, Arthritis and rheumatism.

[46]  S. Wahl,et al.  Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall–Induced Arthritis , 1999, The Journal of experimental medicine.

[47]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.

[48]  J. Esdaile,et al.  Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group--a review of 45 cases. , 1995, The Journal of rheumatology.

[49]  Andreas Radbruch,et al.  Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. , 1999, Arthritis and rheumatism.

[50]  B. Månsson,et al.  Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. , 1995, The Journal of clinical investigation.

[51]  E. Thonar,et al.  Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. , 1993, Arthritis and rheumatism.

[52]  B. Bresnihan,et al.  Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[53]  B. Bresnihan,et al.  Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. , 1993, Arthritis and rheumatism.